CTI BioPharma PT receives Investment Bank Analyst Rating Update
CTI BioPharma (NASDAQ:CTIC) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $12.3 million versus the consensus...
CTI BioPharma Corp. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, IRAK1, FLT3 and CSF1R for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3 and CSF1R.